Zhou C - Search Results

1

A novel bispecific antibody, BiSS, with potent anti-cancer activities.

Dong B, Zhou C, He P, Li J, Chen S, Miao J, Li Q, Wang Z. Dong B, et al. Among authors: zhou c. Cancer Biol Ther. 2016 Apr 2;17(4):364-70. doi: 10.1080/15384047.2016.1139266. Epub 2016 Feb 1. Cancer Biol Ther. 2016. PMID: 26828900 Free PMC article.

2

A novel bispecific antibody, S-Fab, induces potent cancer cell killing.

Li L, He P, Zhou C, Jing L, Dong B, Chen S, Zhang N, Liu Y, Miao J, Wang Z, Li Q. Li L, et al. Among authors: zhou c. J Immunother. 2015 Nov-Dec;38(9):350-6. doi: 10.1097/CJI.0000000000000099. J Immunother. 2015. PMID: 26448579

3

A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells.

Li A, Xing J, Li L, Zhou C, Dong B, He P, Li Q, Wang Z. Li A, et al. Among authors: zhou c. AMB Express. 2016 Dec;6(1):32. doi: 10.1186/s13568-016-0201-4. Epub 2016 Apr 26. AMB Express. 2016. PMID: 27112931 Free PMC article.

4

Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity.

Li J, Zhou C, Dong B, Zhong H, Chen S, Li Q, Wang Z. Li J, et al. Among authors: zhou c. Cancer Biol Ther. 2016 Dec;17(12):1231-1239. doi: 10.1080/15384047.2016.1235659. Epub 2016 Sep 19. Cancer Biol Ther. 2016. PMID: 27645568 Free PMC article.

5

A Bispecific Antibody Based on Pertuzumab Fab Has Potent Antitumor Activity.

Deng W, Liu J, Pan H, Li L, Zhou C, Wang X, Shu R, Dong B, Cao D, Li Q, Wang Z. Deng W, et al. Among authors: zhou c. J Immunother. 2018 Jan;41(1):1-8. doi: 10.1097/CJI.0000000000000200. J Immunother. 2018. PMID: 29232309

6

Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells.

Li Y, Zhou C, Li J, Liu J, Lin L, Li L, Cao D, Li Q, Wang Z. Li Y, et al. Among authors: zhou c. PLoS One. 2018 Jan 22;13(1):e0191024. doi: 10.1371/journal.pone.0191024. eCollection 2018. PLoS One. 2018. PMID: 29357376 Free PMC article.

7

A HER2 bispecific antibody can be efficiently expressed in Escherichia coli with potent cytotoxicity.

Lin L, Li L, Zhou C, Li J, Liu J, Shu R, Dong B, Li Q, Wang Z. Lin L, et al. Among authors: zhou c. Oncol Lett. 2018 Jul;16(1):1259-1266. doi: 10.3892/ol.2018.8698. Epub 2018 May 11. Oncol Lett. 2018. PMID: 29963199 Free PMC article.

8

Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib.

Huang Q, Zhou C, Chen X, Dong B, Chen S, Zhang N, Liu Y, Li A, Yao M, Miao J, Li Q, Wang Z. Huang Q, et al. Among authors: zhou c. PLoS One. 2015 Oct 29;10(10):e0141395. doi: 10.1371/journal.pone.0141395. eCollection 2015. PLoS One. 2015. PMID: 26513662 Free PMC article.

9

BiHC, a T-Cell-Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells.

Xing J, Lin L, Li J, Liu J, Zhou C, Pan H, Shu R, Dong B, Cao D, Li Q, Wang Z. Xing J, et al. Among authors: zhou c. Transl Oncol. 2017 Oct;10(5):780-785. doi: 10.1016/j.tranon.2017.07.003. Epub 2017 Aug 7. Transl Oncol. 2017. PMID: 28797938 Free PMC article.

10

An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL.

Wang Y, Liu Y, Zhou C, Wang C, Zhang N, Cao D, Li Q, Wang Z. Wang Y, et al. Among authors: zhou c. Leuk Lymphoma. 2020 Jul;61(7):1660-1668. doi: 10.1080/10428194.2020.1728746. Epub 2020 Feb 24. Leuk Lymphoma. 2020. PMID: 32091283

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21,233 results

Search Page

Filters